Photodynamic　therapy　(PDT)　has　been　used　as　an　effective　therapeutical　modality　for　tumors.　In　PDT,　a　photosensitizer　was　used　to　capture　the　light　of　specific　wavelength,　leading　to　the　generation　of　reactive　oxygen　species　and　cytotoxicity　surrounding　the　photosensitizer.　Modifications　of　photosensitizers　to　enhance　tumor　specificity　are　common　approaches　to　increase　the　efficacy　and　reduce　the　side　effects　of　PDT.　Previously,　we　developed　a　human　serum　albumin　(HSA)-based　drug　carrier　fused　with　the　human　amino-terminal　fragment　(hATF),　which　binds　to　a　tumor　surface　marker　(urokinase　receptor,　uPAR).　However,　hATF-HSA　binds　to　murine　uPAR　much　weaker　(79-fold)　than　to　human　uPAR,　and　is　not　optimal　for　applications　on　murine　tumor　models.　In　this　study,　we　developed　a　murine　version　of　the　drug　carrier　(mATF-HSA).　A　photosensitizer　(mono-substituted　beta　-carboxy　phthalocyanine　zinc,　CPZ)　was　loaded　into　this　carrier,　giving　a　rather　stable　macromolecule　(mATF-HSA:CPZ)　that　was　shown　to　bind　to　murine　uPAR　in　vitro.　In　addition,　we　evaluated　both　the　photodynamic　therapy　efficacy　and　tumor　retention　capability　of　the　macromolecule　(at　a　dose　of　0.05　mg　CPZ/kg　mouse　body　weight)　on　murine　hepatoma-22　(H22)　tumor　bearing　mouse　model.　mATF-HSA:CPZ　showed　more　accumulation　in　tumors　compared　to　its　human　counterpart　(hATF-HSA:CPZ)　measured　by　quantitative　fluorescence　molecular　tomography　(FMT).　Besides,　mATF-HSA:CPZ　exhibited　a　higher　tumor　killing　efficacy　than　hATF-HSA:CPZ.　Together,　the　macromolecule　mATF-HSA　is　a　promising　tumor-specific　drug　carrier　on　murine　tumor　models　and　is　an　useful　tool　to　study　tumor　biology　on　murine　tumor　models.　C)　2015　Acta　Materialia　Inc.　Published　by　Elsevier　Ltd.　All　rights　reserved.